Ariza-Jimenez, Ana-BelenLeiva Gea, IsabelMartinez-Aedo Ollero, Maria JoseLopez-Siguero, Juan Pedro2025-01-072025-01-072021-11-01https://hdl.handle.net/10668/24524Introduction: Treatment with growth hormone (GH) is not approved for idiopathic short stature (ISS) in Europe. Objectives: To compare the growth of children treated with isolated GH deficiency (IGHD) vs. ISS-treated and untreated children. Methods: A retrospective descriptive study of patients treated in the last 14 years for IGHD (Group A), in comparison with ISS-treated (Group B) and untreated (Group C) subjects. Results: Group A had 67 males, who showed a height gain of 1.24 SD. Group B had 30 boys, who showed a height gain of 1.47 SD. Group C had 42 boys, who showed an improvement of 0.37 SD. The final heights were -1.52 SD, -1.31 SD, and -2.03 SD, respectively. Group A and C did not reach their target heights (with differences of 0.27 SD and 0.59 SD, respectively). Group B surpassed their target height by 0.29 SD. Conclusions: The final heights of the IGHD and treated ISS are similar. Treated groups were taller than untreated groups.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/growth hormone treatmentgrowth hormone deficiencyidiopathic short staturefinal heightFinal heightGh therapyChildrenDiagnosisChildhoodVelocityGainresearch article34768508open access10.3390/jcm102149882077-0383https://www.mdpi.com/2077-0383/10/21/4988/pdf?version=1635680686718583400001